Quantum Genomics SAS: Advancing Cardiovascular Therapies

Quantum Genomics SAS, a France-based biopharmaceutical company, is making significant strides in the health care sector, particularly within the biotechnology industry. The company is dedicated to addressing unmet medical needs in cardiovascular diseases, focusing on conditions such as high blood pressure and heart failure. Quantum Genomics is primarily engaged in the research and development of innovative therapies, with a particular emphasis on Brain Aminopeptidase A Inhibitors (BAPAI), which are aimed at treating cardiovascular diseases.

As of July 1, 2025, Quantum Genomics SAS’s close price on the NYSE Euronext Paris was recorded at 0.0721 EUR. The company’s stock has experienced fluctuations over the past year, reaching a 52-week high of 0.138 EUR on September 29, 2024, and a low of 0.001 EUR on September 4, 2024.

Quantum Genomics is actively involved in four research programs, focusing on the development of new therapies for hypertension and heart failure. The company collaborates with various academic teams, biotechnological research entities, and pharmaceutical and bio-science companies to co-develop products. One of its notable collaborations is with the Center for Clinical Investigation 9201 APHP / INSERM at the Georges Pompidou European Hospital in Paris.

Through these partnerships and its dedicated research efforts, Quantum Genomics SAS continues to push the boundaries of cardiovascular treatment, aiming to bring new and effective therapies to patients in need.